MedTrace Logo

Percutaneous Holmium Injection in Pancreatic Cancer

NCT05880472 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-02-11

No results posted yet for this study

Summary

This investigator initiated study with a medical device aims to assess the safety and feasibility of percutaneous injected holmium-166 microsphere brachytherapy in patients with irresectable pancreatic cancer.

Conditions

  • Pancreas Cancer

Interventions

DEVICE

Intratumoral

Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.

Sponsors & Collaborators

  • Quirem Medical B.V.

    collaborator INDUSTRY

  • Terumo Medical Corporation

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Frank Nijsen, PhD · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-04-22
Completion
2025-04-22

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05880472 on ClinicalTrials.gov